免疫球蛋白对治疗心衰有效
http://www.100md.com
2001年1月16日
NEW YORK (Reuters Health) - People with congestive heart failure may benefit from an infusion of immunoglobulin, a collection of antibodies from donated blood that can protect the body from infection, researchers report.
In a small study of patients with heart failure, those given the intravenous treatment had a decrease in inflammation associated with the condition, and in some cases, appeared to have an increase in the heart's pumping ability. The findings are published in the January 16th issue of Circulation: Journal of the American Heart Association (news - web sites).
, 百拇医药
Besides opening the door to a new type of treatment for heart failure, the results of the study provide more insight into how heart failure works, Dr. Pal Aukrust, of the Research Institute for Internal Medicine in Oslo, Norway, told Reuters Health.
``The study demonstrates a potential for immunomodulating therapy in addition to conventional cardiovascular therapy in the management of heart failure,'' said Aukrust, who is lead author of the study.
, 百拇医药
Congestive heart failure is a condition in which the heart becomes enlarged and begins to pump inefficiently. Symptoms include breathlessness, swelling of the feet due to fluid accumulation, and fatigue. While treatment for the condition has improved, it remains a leading cause of hospitalization in the United States.
In fact, more and more evidence suggests that heart failure involves immunological and inflammatory factors, according to the Norwegian researcher.
, 百拇医药
Inflammation is known to play a role in heart failure, but several sets of researchers have shown that an overactive immune system may also be involved.
Based on studies showing that treatment with immunoglobulin is effective in other immune-related diseases like multiple sclerosis, Aukrust's team conducted a pilot study of the treatment in 40 people with congestive heart failure.
During the 5-month study, half of the patients received a daily intravenous dose of immunoglobulin for 5 days, followed by monthly treatments. The other half received intravenous doses of a placebo fluid, which did not contain any immunoglobulin.
, 百拇医药
Throughout the study, the participants continued taking their normal drugs for heart failure.
Immunoglobulin therapy appeared to improve the heart's pumping abilities, the authors report.
In patients treated with immunoglobulin, 10 had a significant improvement in the heart's pumping capabilities. In contrast, just four patients in the placebo group experienced similar improvements.
And 73% of patients in the treatment group said that their quality of life had improved, compared with 40% of patients in the placebo group, according to the report.
, 百拇医药
Aukrust's team detected several signs that immunoglobulin therapy battles inflammation associated with congestive heart failure. The treatment not only caused substantial increases in several anti-inflammatory factors but also decreased levels of inflammatory factors, which tipped the scales in favor of the anti-inflammatory factors.
Despite the encouraging findings, the authors caution that the study was small. The researchers hope to conduct a larger trial to confirm the results, according to Aukrust.
SOURCE: Circulation 2001;103:220-225., 百拇医药
In a small study of patients with heart failure, those given the intravenous treatment had a decrease in inflammation associated with the condition, and in some cases, appeared to have an increase in the heart's pumping ability. The findings are published in the January 16th issue of Circulation: Journal of the American Heart Association (news - web sites).
, 百拇医药
Besides opening the door to a new type of treatment for heart failure, the results of the study provide more insight into how heart failure works, Dr. Pal Aukrust, of the Research Institute for Internal Medicine in Oslo, Norway, told Reuters Health.
``The study demonstrates a potential for immunomodulating therapy in addition to conventional cardiovascular therapy in the management of heart failure,'' said Aukrust, who is lead author of the study.
, 百拇医药
Congestive heart failure is a condition in which the heart becomes enlarged and begins to pump inefficiently. Symptoms include breathlessness, swelling of the feet due to fluid accumulation, and fatigue. While treatment for the condition has improved, it remains a leading cause of hospitalization in the United States.
In fact, more and more evidence suggests that heart failure involves immunological and inflammatory factors, according to the Norwegian researcher.
, 百拇医药
Inflammation is known to play a role in heart failure, but several sets of researchers have shown that an overactive immune system may also be involved.
Based on studies showing that treatment with immunoglobulin is effective in other immune-related diseases like multiple sclerosis, Aukrust's team conducted a pilot study of the treatment in 40 people with congestive heart failure.
During the 5-month study, half of the patients received a daily intravenous dose of immunoglobulin for 5 days, followed by monthly treatments. The other half received intravenous doses of a placebo fluid, which did not contain any immunoglobulin.
, 百拇医药
Throughout the study, the participants continued taking their normal drugs for heart failure.
Immunoglobulin therapy appeared to improve the heart's pumping abilities, the authors report.
In patients treated with immunoglobulin, 10 had a significant improvement in the heart's pumping capabilities. In contrast, just four patients in the placebo group experienced similar improvements.
And 73% of patients in the treatment group said that their quality of life had improved, compared with 40% of patients in the placebo group, according to the report.
, 百拇医药
Aukrust's team detected several signs that immunoglobulin therapy battles inflammation associated with congestive heart failure. The treatment not only caused substantial increases in several anti-inflammatory factors but also decreased levels of inflammatory factors, which tipped the scales in favor of the anti-inflammatory factors.
Despite the encouraging findings, the authors caution that the study was small. The researchers hope to conduct a larger trial to confirm the results, according to Aukrust.
SOURCE: Circulation 2001;103:220-225., 百拇医药